Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure USA - English USA - Français USA - Deutsch USA - English
illi News/10270608

Trending...
Learn about living with heart failure (HF) and how Cordella improves patient outcomes.
~ Endotronix, Inc., a leading company in the field of heart failure treatment, has recently received Premarket Approval (PMA) from the U.S Food and Drug Administration (FDA) for their innovative Cordella™ Pulmonary Artery (PA) Sensor System. This approval marks a significant milestone for the company and the treatment of heart failure.

The Cordella platform is a revolutionary patient management system that utilizes daily PA pressure and vital signs data to guide therapeutic management and improve patient outcomes. It is the first and only platform to offer comprehensive care using both implanted PA sensors and non-invasive vital sign monitoring in the comfort of a patient's home.

Dr. Liviu Klein, Section Chief of Advanced Heart Failure at the University of California San Francisco and national principal investigator of the PROACTIVE-HF trial, expressed excitement about this approval, stating that it has the potential to transform care for heart failure patients. He also highlighted how Endotronix's solution provides a more complete clinical picture of the patient, allowing providers to make informed decisions remotely between office visits.

More on illi News
The PROACTIVE-HF trial, which served as the basis for FDA approval, demonstrated impressive results with a low rate of heart failure hospitalization and all-cause mortality at 6 months. This further validates the effectiveness of Cordella in improving outcomes for heart failure patients.

In addition to providing critical PA pressure data through an implanted sensor, Cordella also offers other features such as seated PA pressure measurements with a handheld reader, patient visibility into key health trends, secure messaging between clinical teams and patients/caregivers, and reimbursement options through existing pathways.

Harry Rowland, CEO and co-founder of Endotronix, emphasized their belief in using innovation to drive excellence in patient care at home. He stated that this FDA approval is a major milestone for their company and the field of heart failure management. With this approval, they aim to extend optimal therapeutic management to more patients, keeping them out of the hospital and improving their quality of life.

More on illi News
Endotronix plans to launch Cordella in the U.S. later this year and has also submitted a dossier for CE Mark review, with a decision expected in 2025. The company's comprehensive solution, which combines implanted sensors and non-invasive vital sign monitoring, aims to engage patients, reduce congestion, and improve outcomes for those living with heart failure.

In conclusion, Endotronix's Cordella platform has received FDA approval for the treatment of heart failure, making it the first and only PA pressure-guided platform to offer comprehensive patient management at home. This approval is a significant achievement for the company and has the potential to transform care for heart failure patients. With its innovative features and proven results from clinical trials, Cordella is set to make a positive impact on the lives of those living with heart failure.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on illi News